Rigel Announces Start Of Phase 1 Combination Therapy Study Of R763/AS703569 In Advanced Malignancies
Jul 24th 2007Drug InformationBlood
Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) today announced that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has begun enrolling patients in a Phase 1 study to evaluate R763/AS703569 in combination with a standard of care therapy in patients with advanced malignancies. This is the third Phase 1 study planned to evaluate the safety and initial activity of R763/AS703569, a highly potent, orally available Aurora kinase inhibitor. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
